In the first episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, discusses InMed’s biosynthesis platform and its pipeline of cannabinoids with Eric A. Adams, InMed’s CEO, and Alexandra Mancini, senior VP of clinical and regulatory affairs. The discussion also includes the recent FDA public hearing on cannabidiol (CBD) and its implications for the sector.
Gene Online Article: InMed Pharmaceuticals’ Positive Market Response to Cannabinoid Analog INM-901 for Alzheimer’s Treatment
In this article published in Gene Online September 4, 2024, reporter Bernice Lottering writes about InMed’s INM-901 Alzheimer’s disease preclinical study results and the company’s